Findings

What do systematic reviews say?

3,288 questions · 3,354 findings · 516 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 720 · 21.5%GRADE not reported 164 · 4.9%Very low 950 · 28.3%Low 932 · 27.8%Moderate 434 · 12.9%High 154 · 4.6%

Tricyclic antidepressants vs behavioural interventions

Adverse events assessed as reported in paper · children with nocturnal enuresis

1 finding from 1 review

Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 4 participants
Very low

Tricyclic antidepressants vs placebo

Number not achieving 14 consecutive dry nights at the end of treatment ‐ amitriptyline vs placebo · children with nocturnal enuresis

It is very uncertain whether tricyclics changes number not achieving 14 consecutive dry nights at the end of… compared with placebo (very low certainty).

2 findings from 1 review

Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
RR 0.74 [0.61, 0.9]
12 studies · 831 participants
Very low
Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
RR 0.83 [0.72, 0.97]
2 studies · 98 participants
Low

Tricyclic antidepressants vs placebo

Number not achieving 14 consecutive dry nights or relapsing at · children with nocturnal enuresis

Tricyclics showed no clear difference in number not achieving 14 consecutive dry nights or relapsing at compared with placebo (low certainty).

1 finding from 1 review

Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
5 studies · 416 participants
Low

Tricyclic antidepressants vs placebo

Adverse events assessed as reported in paper · children with nocturnal enuresis

1 finding from 1 review

Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 56 participants
Very low

Tricyclic antidepressants vs Other Drug for

Mean number of wet nights a week · children with nocturnal enuresis

2 findings from 1 review

Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 300 participants
Very low
Tricyclic and related drugs for nocturnal enuresis in children 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Very low

Oral ferric maltol vs IV ferric carboxymaltose

Number of responders ‐ disease activity not stated (12 weeks) · IBD patients

Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 0.83 [0.65, 1.06]
1 study · 252 participants
Low

Oral ferric maltol vs IV ferric carboxymaltose

Serious adverse events (12 weeks) · IBD patients

It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 2.95 [0.98, 8.91]
1 study · 252 participants
Very low

Nasogastric vs nasojejunal tube feeding

All‐cause mortality · Severe acute pancreatitis

It is very uncertain whether nasogastric changes mortality compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 0.65 [0.36, 1.17]
5 studies · 220 participants
Very low

Nasogastric vs nasojejunal tube feeding

Organ failure · Severe acute pancreatitis

It is very uncertain whether nasogastric changes organ failure (single or multiple) compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 0.99 [0.79, 1.25]
3 studies · 145 participants
Very low

Nasogastric vs nasojejunal tube feeding

Rate of infection (local or systemic) · Severe acute pancreatitis

It is very uncertain whether nasogastric changes rate of infection (local or systemic) compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 0.76 [0.44, 1.3]
2 studies · 108 participants
Very low

Nasogastric vs nasojejunal tube feeding

Success of the procedure · Severe acute pancreatitis

It is very uncertain whether nasogastric changes success rate of the procedure compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 1.06 [0.93, 1.2]
3 studies · 159 participants
Very low

Nasogastric vs nasojejunal tube feeding

Procedure‐related general complications · Severe acute pancreatitis

It is very uncertain whether nasogastric changes complications associated with the procedure compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 0.52 [0.07, 3.74]
2 studies · 80 participants
Very low

Nasogastric vs nasojejunal tube feeding

Surgical intervention · Severe acute pancreatitis

It is very uncertain whether nasogastric changes surgical intervention compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 0.87 [0.3, 2.5]
3 studies · 145 participants
Very low

Nasogastric vs nasojejunal tube feeding

Requirement for parenteral nutrition · Severe acute pancreatitis

It is very uncertain whether nasogastric changes requirement for parenteral nutrition compared with nasojejunal tube feeding (very low certainty).

1 finding from 1 review

Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis 2020 · Cochrane Headline outcomes only
RR 1.03 [0.39, 2.71]
2 studies · 80 participants
Very low

Pericyazine vs Typical antipsychotics

Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia

It is very uncertain whether pericyazine changes global state ‐ not improved compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.24 [0.93, 1.66]
2 studies · 122 participants
Very low

Pericyazine vs atypical antipsychotics

Mental state ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.46 [0.11, 1.9]
1 study · 93 participants
Very low

Pericyazine vs atypical antipsychotics

Behaviour ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pericyazine vs atypical antipsychotics

Economic outcome ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pericyazine vs Typical antipsychotics

Relapse · patients with schizophrenia

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low